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Abstract
There is evidence that multiple sclerosis (MS) may associated with cognitive impairment in 25 to
40% of cases. The gene encoding myeloperoxidase (MPO) is involved in molecular pathways leading
to β-amyloid deposition. We investigated a functional biallelic (G/A) polymorphism in the promoter
region (-463) of the MPO gene in 465 patients affected by MS, divided into 204 cognitively normal
and 261 impaired. We did not find significant differences in allele or genotype distributions between
impaired and preserved MS patients. Our findings suggest that MPO polymorphism is not a risk
factor for cognitive impairment in MS.
Findings
Multiple sclerosis (MS) is a chronic inflammatory disease
of the central nervous system (CNS), characterised by pri-
mary demyelination with relative axonal sparing and by a
clinical course that varies from relapsing remitting (RR) to
chronic progressive (CP). Cognitive dysfunction occurs in
25–40% of patients with MS, and it is often a major cause
of disability in patients with the disease [1]. Although the
pathogenesis of MS is not fully understood the role of
genetic factors is firmly established [2]. Such a genetic fac-
tor might be better identified through association studies
which look for an increased frequency of a particular
genetic marker or allele among the affected individuals as
compared to unaffected individuals. The myeloperoxidase
(MPO) gene encodes for an enzyme that catalyses a reac-
tion between hydrogen peroxide and chloride to generate
hypochlorous acid, a potent oxidant leading to oxidising
conditions that are known to increase β-amiloid protein
(Aβ) deposition [3]. The MPO gene, at 17q23.1, contains
a functionally important G to A base substitution poly-
morphism, 463 bases upstream from the transcription
start site, which has been found to cause a decreased tran-
scriptional activity in cellular transfection assays due to
the destruction of an SP1 binding site [4]. A few studies
have investigated the -463 G/A MPO promoter polymor-
phism in MS. Nagra and co-workers [5] found an overrep-
resentation of the GG genotype in women with early
onset MS. Two subsequent studies found no association
between the MPO promoter polymorphism and MS [6,7].
In a recent work Zakrewska-Pniewska and co-workers ana-
lysed the relationship between APOE and MPO genes'
polymorphisms and MS, and they found that the geno-
type GG of MPO was related to more pronounced brain
atrophy [8]. Owing to the protein product of the MPO
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gene being involved in AD pathology, possibly through
oxidation of Aβ or ApoE, promoting their aggregation into
insoluble complexes, or directly through oxidation-
induced damage to associated neurons [9], there is bio-
logic evidence implicating MPO in the cognitive decline
in patients with MS, but no definite data are currently
available on the possible role of MPO polymorphism in
the development of cognitive decline in MS. This study
was mainly designed to investigate whether some clinical
and individual variables and the occurrence of the -463 G/
A promoter polymorphism of the MPO gene may be asso-
ciated with cognitive impairment in patients with MS. The
sample included in this study consisted of 465 patients
affected by MS data on our patients were reported in
greater detail elsewhere [10]. Informed consent to per-
form molecular genetic studies was obtained from all
patients.
Genomic DNA was prepared from leukocytes harvested
from whole blood using standard methods. The PCR-
RFLP based assay was used to characterise the wild-type
(G) and variant (A) MPO alleles at position -463 [11]. Sta-
tistical analyses were performed with Statistical Package
for Social Sciences software SPSS (version 12.0, Chicago,
IL, USA) for Windows '98/'00. In our sample of consecu-
tive patients affected by MS, we found the cognitive dete-
rioration was present at different degrees of severity in the
majority of the patients. More in detail, two-hundred and
four patients (44%) were found to be cognitively pre-
served by the neuropsychological evaluation, whereas 261
(56%) failed at least one test and were therefore consid-
ered cognitively impaired. The cognitively impaired group
differed from the preserved group in the following charac-
teristics: a longer disease duration, a high EDSS score, a
greater proportion of individuals with secondary progres-
sive form and a lower education. No difference was found
in the number of failed neuropsychological test among
subjects with different polymorphic variants (p = 0.805;
Kruskal-Wallis test). No significant difference was found
in the genotypic (p = 0.649; Pearson χ2-test) or allelic dis-
tribution (p = 0.517; Pearson χ2-test) of the -463 G/A pro-
moter polymorphism of the MPO gene between preserved
and impaired subjects (Table). Furthermore, considering
a power of 80% and a significance level of 0.05, the power
calculation for the A allele shows that the ORs detectable
as significant resulted lower than 0.618 and higher than
1.527. These results suggest that the -463 G/A promoter
polymorphism of the MPO gene does not confer a risk of
cognitive impairment in patients with MS.
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Table 1: Genotypes and allele frequencies of the MPO polymorphism
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Allele frequency
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G 314 (77.0%) 411 (78.7%) 1.0
*Odds Ratios and CI were estimated using logistic regression adjusted for age and sex.Publish with BioMed Central    and   every 
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